Phaseline

Targets › GSR

GSR (Glutathione reductase, mitochondrial): drug programs, companies and trials

1 program from 1 company in 8 trials: 5 Phase 2, 3 Phase 1; Neurology, Oncology; next expected readout Dec 2028.

Catalyzes the reduction of glutathione disulfide (GSSG) to reduced glutathione (GSH). Constitutes the major mechanism to maintain a high GSH:GSSG ratio in the cytosol. (UniProt, P00390)

Open in Phaseline: the race on GSR, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
General OncologyCarmustine
Glutathione reductase inhibitor
GSRPhase 1Pancreatic Adenocarcinoma Metastatic; Metastatic Malignant Neoplasm in the Liver; Glioblastoma Multiforme; Non-Hodgkin Lymphoma …Dec 2028

Conditions

Glioblastoma Multiforme (2) Pancreatic Adenocarcinoma Metastatic (1) Metastatic Malignant Neoplasm in the Liver (1) Non-Hodgkin Lymphoma (1) Brain Tumor - Metastatic (1) Autoimmune Disease (1) Metastatic Uveal Melanoma (1)

Modalities

small molecule (1)

Companies

General Oncology (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.